Company news
Theralase Technologies Inc. news in 2018
Theralase Technologies Inc.'s news releases, calls and decks from 2018, newest first.
Health Canada Grants ITA Approval to Commence Phase II Clinical Study
December 10, 2018
Theralase's Rutherrin(R) Photo Dynamic Therapy Induces Immune Response to Destroy Human Brain Cancer Cells
November 30, 2018
Theralase Release 3Q2018 Financial Statements
November 29, 2018
Theralase(R) Granted Canadian Anti-Cancer Patent
November 15, 2018
Patient Five Cancer-Free After Single PDT Treatment
November 8, 2018
Theralase® Anti-Cancer Technology Shows Promise for Esophageal Cancer Using Targeted Molecular Delivery System
October 9, 2018
Theralase Announces Completion of Non-Brokered Private Placement for Approximately $1.1 million
October 3, 2018
Health Canada Approves Commencement of Phase II Clinical Study
September 10, 2018
Theralase's Lead Photodynamic Compound TLD-1433 Provides New Opportunities in Targeted Cancer Therapy
September 4, 2018
Theralase Announces Proposed Non-Brokered Private Placement of up to $10 Million
August 28, 2018
Theralase® Provides Update on Upcoming Initiatives for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
August 27, 2018
Theralase Submits Phase II Bladder Cancer Clinical Study Application to Health Canada for Review and Approval
August 20, 2018
Theralase Achieves Exploratory Efficacy Endpoint in Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study for Patients Five and Six
August 13, 2018
Theralase Release 2Q2018 Financial Statements
July 26, 2018
BTV Reveals Novel Cancer Treatment, Cannabis and Lithium Companies
July 26, 2018
Theralase Demonstrates Anti-Cancer Technology Prevents Recurrence of Bladder Cancer at 180 Days Post-Treatment
July 16, 2018
Theralase Releases AGM Videos
June 29, 2018
Theralase Researchers Receive Government Grant
June 28, 2018
Theralase Strengthens Its Patent Portfolio with an Additional US Patent Covering Metal-Glycoprotein Complexes, Including Rutherrin® Based Photo Dynamic Therapy, in Immune Privileged Sites
June 22, 2018
Theralase® Demonstrates Significant Advantage in Treatment of Brain Tumours
June 11, 2018
Theralase Demonstrates 36 Months Stability of Lead Anti-Cancer Drug
June 6, 2018
Theralase Release 1Q2018 Financial Statements
May 30, 2018
Theralase Successfully Completes Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
May 30, 2018
Theralase Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
May 17, 2018
Theralase Announces Completion of Non-Brokered Private Placement of Units for Aggregate Gross Proceeds of Approximately $1.02 million
May 14, 2018
Theralase Announces Proposed Non-Brokered Private Placement of up to $1 Million
May 8, 2018
Theralase Increases Revenue 22% for 2017 Financial Statements
April 30, 2018
Theralase Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study
April 16, 2018
Theralase Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer
March 27, 2018
Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells
March 15, 2018
Rutherrin® Technology Granted Allowance for Canadian Patent
March 7, 2018
Theralase Advances Anti-Cancer Technology in Destruction of Human Lung Cancer
March 5, 2018
Theralase Announces Settlement Agreement with Ontario Securities Commission
February 26, 2018
Theralase Anti-Cancer Technology Treats Sixth Patient for Bladder Cancer
February 9, 2018
Correcting and Replacing: Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer
January 18, 2018
Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer
January 18, 2018
Theralase Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer
January 17, 2018